SynthesisFrontiers in endocrinology2026
Oral Chinese herbal formulas for premature ovarian insufficiency: a systematic review, meta-analysis, and exploratory therapeutic-principle subgroup analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Premature ovarian insufficiency (POI) is characterized by impaired ovarian endocrine function and reduced ovarian reserve. Methods: We searched eight bibliographic databases, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), and the Chinese Clinical Trial Registry (ChiCTR) from inception to May 30, 2026, for parallel-group randomized controlled trials comparing HRT-based regimens with pure oral Chinese herbal formulas within three prespecified therapeutic-principle categories. This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD420251234457). Results: Menstrual return or resumption was designated as the patient-important outcome, while follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH) were designated as primary surrogate biomarkers. Forty-one HRT-controlled trials met the prespecified therapeutic-principle criteria. No clear between-group difference was detected for menstrual return or resumption (4 studies, 266 participants; odds ratio [OR] 1.523, 95% confidence interval [CI] 0.315 to 7.371; I Discussion: Current evidence does not support the routine use of any specific Chinese herbal formula or therapeutic-principle category. Guideline-based management, including HRT when clinically appropriate, should remain standard care, and rigorously designed multicenter trials using patient-important outcomes and standardized safety reporting are needed. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251234457.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.